The round was led by Altimeter Capital, joined by returning investors Radical Ventures, Wittington Ventures, Mubadala Capital, Epic Ventures, and Necessary Venture Capital. This round of funding was secured to propel the company's mission to advance AI to eliminate trial and error in medicine by investing in its people, data, engineering capabilities, and longer-term R&D initiatives.

Unlearn is a technology company advancing AI to eliminate trial and error in medicine. Unlearn's technology powers the clinical trials of leading global pharmaceutical companies, helping them to reach full enrollment faster and bring new treatments to patients sooner. Their methods using participants' digital twins are qualified by the European Medicines Agency and align with current FDA guidance.